The molecule was probably right. The conversation was missing.

A man I once heard about told the same story everyone in his support group seemed to tell. He had gone to his GP, said he could not get out of bed, and walked out ten minutes later with a prescription. The pills helped. He said that part plainly, without resentment. What stayed with him was the ten minutes. He had wanted to say a great deal more about why the bed had become impossible, and the conversation had ended before he reached it. Years later, still on the same prescription that no one had revisited, the way he put it was this: he had been quieted, not heard.

It is tempting to read that as an argument against the pills. I want to set that reading aside at the start, because the evidence does not support it. In Dutch primary care, 94.6% of antidepressant use was found to be in line with the national GP guideline (Piek et al., 2011). The authors split it carefully, just under half clearly justified and just under half plausibly so, with only 5.4% they could not justify at all. So the decision to start the medication is, in the great majority of cases, the right clinical call. If the wound this man is describing were really about the molecule, the numbers would look very different. They don't.

So what is he describing? Read the same researchers a little further and they hand you the answer. The gap they found was not at the prescription. It was in what happened, or didn't, around and after it.

The conversation thins as the prescription lengthens

Look at what the medication does over time rather than at the moment it starts. In a nationwide GP cohort of 326,025 patients across 189 practices, of those on four or more antidepressant prescriptions in the first year, 42% were still being prescribed them in every one of the five years studied, and 65% were still there a year later (Verhaak et al., 2019). Those are not pictures of a wrong decision. They are pictures of a decision that was made once and then carried forward, year after year, often without anyone stopping to ask whether it was still the right one. Still working? Still needed? Still wanted? Nobody asks, because asking is the part that quietly drops off the schedule. The authors say it more plainly than I can: proactive medication reviews, they write, have been reported to become increasingly sparse the longer antidepressants have been prescribed. Read that twice. The review thins out exactly as the prescription lengthens. The conversation gets quieter at precisely the point the patient has been on the drug long enough to have something to say about it.

This is not one cohort's quirk. An institute that monitors Dutch prescribing found antidepressants used longer than recommended in 40 to 50% of users, noted that the reasons for that extended use are barely documented anywhere, and made a recommendation that tells you where the problem sits: that doctors and pharmacists discuss the intended duration of treatment at the start (IVM). When the body watching the prescribing pattern decides the fix is "have the conversation," you can stop wondering whether the trouble is the chemistry.

Treated kindly, decided about

Here is the part that should land closest to home, because it is not about pills at all. A patient panel of more than 750 people and their relatives found that roughly two of three do not co-decide on their own diagnosis and treatment (MIND). What did they say they wanted? Not less care. They wanted information, shared goals, and a real choice among the options in front of them. It echoes a pattern clinicians will recognise: patients often value being treated with warmth and respect, while the sense of a real say in the decision lags behind. Sit with that combination for a second. People feel treated kindly and decided about at the same time. The warmth is real. The voice in the decision is missing.

That is the shape of "drugged into silence," once you stop reading it as a verdict on the drug. It is the experience of a decision made over a person rather than with them, in a system that was, on the medical merits, mostly doing the right thing. So what is the remedy? Not a smaller dose. The Dutch standard of care already names it: in the generic module on shared decision-making, the patient is described as the expert on their own experience, wishes and preferences, with input equal to the clinician's. The thing this man wanted in his ten minutes is not a complaint against medicine. It is the codified norm of the care he was receiving, quietly going unmet.

Could it be otherwise? The research suggests it could. When a team mapped what patients and professionals each need to make a genuine shared decision about coming off antidepressants, they found the two groups did not even weigh the same things equally, diverging on how much "professional guidance" the conversation required (Wentink et al., 2019). In other words, patient and clinician were not yet in the same conversation, which is precisely the thing you can build toward rather than around. Another Dutch team designed a trial to test whether structured shared decision-making could lower the conflict patients feel about their own treatment choices (Metz et al., 2015). You do not design a trial against something you believe is fixed. The deficit is treated, by the people who study it, as addressable.

So what was the man in the support group actually telling us? Not that his medication was wrong; 94.6% of the time, on the evidence, it isn't. He was telling us that being prescribed and being heard are two different events, and that his care had managed the first without the second. The pills were never the silence. The silence was the conversation that ended at ten minutes and was never reopened.

If you carry one figure out of this, carry the gentlest one. Roughly two of three patients say they did not get to co-decide. Now count your own. Picture the people on your list who are continuing on something started a year ago, two years ago, by someone in a hurry on a hard morning, and ask how many of them have been asked, since, what they make of it. The molecule, for most of them, was probably the right call. The question is whether anyone has had the other half of the conversation yet.

Researched by Freudche.